60923-15-1

Usage

Chemical Family

2-(aminomethyl)-5-(benzyloxy)-4H-pyran-4-one belongs to the pyranone family of chemical compounds.

Functional Groups

It contains an amino group (-NH2) and a benzyl ether group (C6H5-O-CH2-), which provide versatility in organic synthesis.

Versatility

The compound can be used as a building block for the synthesis of various pharmaceutical compounds.

Medicinal Chemistry Applications

It has potential applications in medicinal chemistry for the development of new drugs and biologically active molecules.

Biological Activities

The pyranone scaffold of the compound has been studied for its potential biological activities, making it an interesting target for further research and development.

Upstream product

• 812653-96-6 2-phthalimidomethyl-5-benzyloxypyran-4-one 
• 7559-81-1 chlorokojic acid 
• 60923-13-9 2-(azidomethyl)-5-hydroxy-4H-pyran-4-one 
• 1617516-52-5 2-(azidomethyl)-5-(benzyloxy)-4H-pyran-4-one 
• 89539-54-8 5-(benzyloxy)-2-(chloromethyl)-4H-pyran-4-one 
• 100-39-0 benzyl bromide 
• 100-44-7 benzyl chloride 
• 15771-06-9 5-benzyloxy-2-hydroxymethyl-4H-pyran-4-one 
• 501-30-4 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one 

Downstream Products

• 812653-57-9 7-methoxy-N-[(5-benzoxy-4-oxo-4H-pyran-2-yl)methyl]-2-oxo-2H-chromene-3-carboxyamide 
• 812653-55-7 N-[(5-benzoxy-4-oxo-4H-pyran-2-yl)methyl]-2-(7-methoxy-2-oxo-2H-chromen-4-yl)acetamide 
• 812653-56-8 N-[(5-benzoxy-4-oxo-4H-pyran-2-yl)methyl]-2-(6,7-dimethoxy-2-oxo-2H-chromen-4-yl)acetamide 
• 1617517-28-8 6-(benzenesulfonylamino-methyl)-3-benzyloxy-1-methyl-4-oxo-1,4-dihydro-pyridine-2-carboxylic acid methylamide 
• 1617516-80-9 N-((5-(benzyloxy)-4-oxo-4H-pyran-2-yl)methyl)benzenesulfonamide 
• 1617516-81-0 N-(5-hydroxy-6-hydroxymethyl-4-oxo-4H-pyran-2-ylmethyl)-benzene sulfonamide 
• 1617516-82-1 N-(5-benzyloxy-6-hydroxymethyl-4-oxo-4H-pyran-2-ylmethyl)-benzene sulfonamide 
• 1617516-83-2 N-(5-benzyloxy-6-formyl-4-oxo-4H-pyran-2-ylmethyl)-benzene sulfonamide 
• 1617516-79-6 N-(5-benzyloxy-4-oxo-4H-pyran-2-ylmethyl)-benzenesulfonamide 
• 1617517-35-7 6-(benzenesulfonylamino-methyl)-3-benzyloxy-1-methyl-4-oxo-1,4-dihydro-pyridine-2-carboxylic acid isopropylamide 
• 1617516-84-3 6-(benzenesulfonylamino-methyl)-3-benzyloxy-4-oxo-4H-pyran-2-carboxylic acid 
• 1617516-85-4 6-(benzenesulfonylamino-methyl)-3-benzyloxy-1-methyl-4-oxo-1,4-dihydro-pyridine-2-carboxylic acid 
• 1617516-53-6 6-(benzenesulfonylamino-methyl)-3-hydroxy-1-methyl-4-oxo-1,4-dihydro-pyridine-2-carboxylic acid 
• 68642-92-2 2-(acetylamino-methyl)-5-benzyloxy-pyran-4-one 

Relevant academic research and scientific papers

COMPOSITIONS AND METHODS FOR INHIBITING INFLUENZA RNA POLYMERASE PA ENDONUCLEASE

There are provided inter alia metalloenzyme inhibitors, such as inhibitors of influenza A RNA dependent RNA polymerase PA subunit endonuclease, and methods of synthesis and use of the same.

Fragment-Based Identification of Influenza Endonuclease Inhibitors

The influenza virus is responsible for millions of cases of severe illness annually. Yearly variance in the effectiveness of vaccination, coupled with emerging drug resistance, necessitates the development of new drugs to treat influenza infections. One a

PYRIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELORIATION OR PREVENTION OF A VIRAL DISEASE

The present invention relates to a compound having the general formula (II), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

Design, synthesis, physicochemical properties, and evaluation of novel iron chelators with fluorescent sensors

The synthesis of a range of novel 3-hydroxypyridin-4-ones and 3-hydroxypyran-4-ones linked with different coumarin substituents is described. These compounds have been developed in order to provide a series of molecular probes for the quantification of intracellular labile iron pools. An evaluation of the effect of iron(III) on fluorescence intensity was undertaken. Chelation of iron(III) causes quenching of fluorescence. The relationship between iron(III) concentration and the extent of fluorescence quenching indicates that the metal is chelated in a complex with a metal-to-ligand stoichiometry of 1:3. The fluorescence of hydroxypyridinone compounds was found to be more efficiently quenched by iron(III) than were the hydroxypyranones. The metal-to-ligand stoichiometry at which maximum quenching is observed was found to depend on the site at which coumarin is attached. The efficiency of fluorescence quenching by iron(III) is markedly influenced by solvent polarity and pH. The permeability of two representative fluorescent chelators across human erythrocyte ghost membranes was investigated. The rate of permeability for a series of probes was found to be related to the corresponding ClogP values.